NPNicole Carolina Sotomayor Páez

Nicole Carolina Sotomayor Páez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nicole Carolina Sotomayor Páez has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Optimized Antifibrotic Therapy on Cardiac and Pulmonary Function in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review of Diagnostic and Therapeutic Approaches

    by Syndy Katherine Guarin-Rivera, Gabriela Patricia Guijarro Reinoso, Norma Susana Chávez Villagómez, Jonattan Palacios Torres, Dario Javier Caguate Miranda, Nicole Carolina Sotomayor Páez, Alexander David Silva, Edgar Felipe Carranza Vargas, Pedro Ergir Tomay Madrigal

    Idiopathic Pulmonary Fibrosis (IPF) is progressive interstitial lung disease which is characterized by fibrosis of lung tissue which impair respiratory function and is seen with high mortality. Our systematic review evaluates impact of optimized antifibrotic therapies while including pirfenidone, nintedanib, and BI 1015550 on pulmonary and cardiac function in IPF patients. Comprehensive analysis with previous randomized controlled trials, cohort studies and observational data was performed to assess efficacy in slowing forced vital capacity (FVC) decline, improving prognosis and managing adverse events. Our findings indicate that antifibrotic therapies can mitigate FVC decline and reduce mortality with pirfenidone and nintedanib have shown tolerable safety profiles. BI 1015550 have also shown promising results in preventing FVC reduction and pulmonary rehabilitation alongside antifibrotic treatment improved endurance but not functional capacity. Reported limitations of the included studies include variability in study designs and potential biases from non-randomized trials. Despite these challenges antifibrotic therapies represent a critical advancement in IPF management preserving lung function and potentially enhancing quality of life.